ILMN vs WAT vs IQV
161 measures in 16 categories, one definition each, computed from filings and market data.
ILMN57.6
Illumina, Inc.
Healthcare · Medical - Diagnostics & Research
$262.54 −2.01%$39.6B mkt cap
Score DNA
WAT46.5
Waters Corporation
Healthcare · Medical - Diagnostics & Research
$436.95 −1.60%$42.9B mkt cap
Score DNA
IQV56.4
IQVIA Holdings Inc.
Healthcare · Medical - Diagnostics & Research
$266.90 −1.49%$43.9B mkt cap
Score DNA
Price, rebased to 100 three years ago
ILMN WAT IQV · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 0 | 0 | 0 |
| Last Congress purchase | — | — | — |
| 13F net change in holders | +92 | +10 | +23 |
| ETFs adding shares, 30d | 1,058 | 1,174 | 1,126 |
| ETFs trimming, 30d | 840 | 1,004 | 1,089 |
| Net ETF funds, 30d | +218 | +170 | +37 |
Valuation
16 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| P/E (TTM) | 48.1x
82nd
|
258.2x
100th
|
32.0x
35th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | — | 2.76
62nd
|
| Price / sales | 8.8x
76th
|
9.2x
79th
|
2.6x
24th
|
| Price / book | 14.0x
89th
|
2.8x
33rd
|
7.1x
70th
|
| Price / tangible book | 23.6x
71st
|
— | — |
| Price / free cash flow | 42.2x
79th
|
107.7x
89th
|
16.8x
5th
|
| Price / operating cash flow | 36.2x
78th
|
78.0x
87th
|
15.6x
13th
|
| Enterprise value | $41.0B
76th
|
$47.6B
83rd
|
$58.1B
93rd
|
| EV / sales | 9.1x
76th
|
10.3x
83rd
|
3.4x
31st
|
| EV / EBITDA | 29.5x
76th
|
53.2x
81st
|
16.5x
24th
|
| EV / EBIT | 36.8x
76th
|
141.1x
100th
|
24.8x
29th
|
| EV / free cash flow | 43.7x
74th
|
119.5x
89th
|
22.2x
11th
|
| Earnings yield | 2.1%
52nd
|
0.4%
41st
|
3.1%
79th
|
| FCF yield | 2.4%
48th
|
0.9%
41st
|
5.9%
97th
|
| Operating cash flow yield | 2.8%
38th
|
1.3%
31st
|
6.4%
90th
|
| Graham number (per share) | $47.44
35th
|
$76.74
59th
|
$81.95
71st
|
Profitability (TTM)
12 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Gross margin | 66.8%
79th
|
50.8%
45th
|
26.2%
14th
|
| EBITDA margin | 30.9%
86th
|
19.3%
59th
|
20.8%
62nd
|
| Operating margin | 21.0%
79th
|
8.0%
41st
|
13.6%
62nd
|
| EBIT margin | 24.8%
90th
|
7.3%
45th
|
13.8%
62nd
|
| Net margin | 18.4%
79th
|
3.6%
41st
|
8.1%
52nd
|
| NOPAT margin | 17.0%
72nd
|
6.4%
41st
|
11.4%
66th
|
| FCF margin | 20.9%
79th
|
8.6%
45th
|
15.4%
59th
|
| Operating cash flow margin | 24.4%
83rd
|
11.8%
38th
|
16.6%
55th
|
| R&D / revenue | 21.3%
86th
|
6.9%
48th
|
0.0%
0th
|
| SG&A / revenue | 24.1%
31st
|
26.1%
45th
|
12.1%
10th
|
| Stock comp / revenue | 1.6%
29th
|
1.6%
32nd
|
1.6%
36th
|
| Effective tax rate | 18.7%
41st
|
19.1%
45th
|
15.7%
24th
|
Returns on capital
11 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| ROE (on average equity) | 32.4%
93rd
|
1.9%
41st
|
23.0%
81st
|
| ROA | 13.0%
86th
|
1.1%
41st
|
4.7%
59th
|
| ROIC | 18.2%
86th
|
1.5%
38th
|
9.6%
69th
|
| ROCE | 22.0%
90th
|
1.5%
41st
|
11.1%
79th
|
| Return on tangible assets | 17.5%
90th
|
2.3%
41st
|
8.0%
69th
|
| Cash ROIC (OCF / invested capital) | 26.1%
83rd
|
2.8%
28th
|
13.9%
62nd
|
| Gross profitability (GP / assets) | 45.1%
76th
|
9.5%
10th
|
14.9%
28th
|
| ROIC, 3-yr average | -15.2%
17th
|
12.4%
88th
|
7.3%
79th
|
| ROIC, 5-yr average | -22.8%
17th
|
25.2%
92nd
|
7.6%
71st
|
| ROE, 5-yr average | -38.2%
16th
|
68.1%
92nd
|
21.1%
84th
|
| Incremental ROIC | -50.5%
26th
|
-1.4%
52nd
|
96.4%
81st
|
Growth
17 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Revenue growth (TTM YoY) | 4.9%
29th
|
52.5%
100th
|
8.2%
54th
|
| Revenue growth (QoQ) | 6.2%
38th
|
29.8%
93rd
|
5.2%
28th
|
| Revenue CAGR, 3 yr | 0.2%
15th
|
15.8%
78th
|
5.0%
52nd
|
| Revenue CAGR, 5 yr | 2.5%
30th
|
11.7%
63rd
|
5.6%
48th
|
| Gross profit CAGR, 3 yr | 2.6%
33rd
|
10.4%
67th
|
-4.5%
19th
|
| Operating income CAGR, 3 yr | — | -24.3%
0th
|
7.7%
53rd
|
| Net income growth (TTM YoY) | -34.4%
12th
|
-74.9%
0th
|
11.2%
44th
|
| Net income CAGR, 3 yr | — | -37.3%
8th
|
7.9%
67th
|
| EPS growth (TTM YoY) | -32.3%
12th
|
-84.7%
0th
|
14.2%
44th
|
| EPS CAGR, 3 yr | — | -47.1%
0th
|
11.6%
83rd
|
| EPS CAGR, 5 yr | 0.6%
57th
|
-30.8%
0th
|
21.2%
86th
|
| FCF growth (TTM YoY) | -8.9%
22nd
|
-35.7%
6th
|
30.0%
72nd
|
| FCF CAGR, 3 yr | — | 1.0%
21st
|
18.2%
71st
|
| Operating cash flow CAGR, 3 yr | 73.4%
88th
|
-1.3%
18th
|
7.9%
47th
|
| Book value CAGR, 3 yr | -23.5%
4th
|
127.9%
100th
|
5.9%
64th
|
| Dividend CAGR, 3 yr | — | — | — |
| Sustainable growth rate | 32.4%
88th
|
1.9%
0th
|
23.0%
69th
|
Margin history & stability
7 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Gross margin, 3-yr average | 65.1%
82nd
|
56.5%
57th
|
31.3%
21st
|
| Operating margin, 3-yr average | -2.8%
39th
|
20.8%
82nd
|
13.6%
64th
|
| Net margin, 3-yr average | -7.0%
32nd
|
15.3%
82nd
|
8.5%
68th
|
| FCF margin, 3-yr average | 17.7%
75th
|
16.1%
68th
|
13.4%
57th
|
| Revenue stability (0-1) | 0.55
21st
|
0.56
25th
|
0.98
93rd
|
| Earnings stability (0-1) | 0.01
4th
|
0.49
57th
|
0.64
75th
|
| Margin stability (0-1) | 0.95
57th
|
0.94
54th
|
0.89
43rd
|
Liquidity (latest quarter)
7 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Cash & short-term investments | $1.2B
86th
|
$539.0M
52nd
|
$2.1B
93rd
|
| Net cash (− = net debt) | −$1.4B
45th
|
−$4.7B
17th
|
−$14.2B
7th
|
| Working capital | $1.3B
83rd
|
$2.1B
90th
|
−$2.6B
0th
|
| Current ratio | 1.80
38th
|
1.86
45th
|
0.71
0th
|
| Quick ratio | 1.40
31st
|
1.29
28th
|
0.71
0th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.74
38th
|
0.22
14th
|
0.24
21st
|
| Defensive interval (days) | 342 days
24th
|
464 days
48th
|
928 days
86th
|
Leverage & solvency (latest quarter)
13 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Total debt | $2.5B
66th
|
$5.3B
83rd
|
$16.2B
93rd
|
| Debt / equity | 0.89
85th
|
0.35
37th
|
2.63
96th
|
| Net debt / equity | 0.48
70th
|
0.31
52nd
|
2.29
96th
|
| Debt / assets | 38.0%
79th
|
21.2%
31st
|
54.4%
90th
|
| Debt / capital | 47.1%
82nd
|
25.7%
36th
|
72.5%
93rd
|
| Debt / EBITDA | 1.82
24th
|
5.87
81st
|
4.60
76th
|
| Net debt / EBITDA | 0.98
24th
|
5.26
90th
|
4.01
81st
|
| Interest coverage (EBIT / interest) | 11.2x
76th
|
2.4x
44th
|
3.0x
52nd
|
| Cash interest coverage | 10.9x
68th
|
4.0x
32nd
|
3.7x
28th
|
| Debt payback (years of OCF) | 2.3 yrs
35th
|
9.6 yrs
91st
|
5.8 yrs
78th
|
| Liabilities / assets | 57.3%
76th
|
38.6%
31st
|
78.9%
90th
|
| IS credit model rating | AA | BBB | BB |
| Implied credit spread (bps) | 80
14th
|
275
66th
|
475
76th
|
Efficiency
11 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Asset turnover | 0.71
69th
|
0.32
21st
|
0.58
55th
|
| Fixed asset turnover | 4.06
45th
|
2.50
21st
|
19.96
100th
|
| Inventory turnover | 2.5
4th
|
2.4
0th
|
— |
| Receivables turnover | 6.1
38th
|
3.4
3rd
|
7.1
66th
|
| Days sales outstanding | 60 days
62nd
|
107 days
97th
|
52 days
34th
|
| Days inventory outstanding | 147 days
96th
|
153 days
100th
|
— |
| Days payables outstanding | 53 days
66th
|
77 days
90th
|
102 days
100th
|
| Cash conversion cycle (days) | 155 days
93rd
|
183 days
100th
|
−51 days
0th
|
| Capex / revenue | 3.5%
52nd
|
3.3%
41st
|
1.2%
7th
|
| Capex / depreciation | 0.57
34th
|
0.27
14th
|
0.17
10th
|
| Operating expense ratio | 45.3%
52nd
|
49.8%
55th
|
21.3%
17th
|
Cash flow & earnings quality
7 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Operating cash flow / net income | 1.33
35th
|
3.31
94th
|
2.05
82nd
|
| FCF / net income | 1.14
47th
|
2.40
94th
|
1.90
82nd
|
| FCF / operating cash flow | 85.8%
65th
|
72.5%
48th
|
92.7%
91st
|
| Capex / operating cash flow | 14.2%
35th
|
27.5%
52nd
|
7.3%
9th
|
| Accruals ratio | -4.2%
52nd
|
-2.6%
76th
|
-4.9%
41st
|
| Sloan accruals ratio | -3.1%
34th
|
5.0%
79th
|
-8.7%
7th
|
| Earnings quality score (0-1) | 1.00
24th
|
1.00
24th
|
1.00
24th
|
Scores & forensic checks
15 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| IS score | 58
59th
|
47
41st
|
56
55th
|
| IS profitability | 80
93rd
|
16
21st
|
45
59th
|
| IS growth | 28
7th
|
40
25th
|
55
46th
|
| IS value | 29
7th
|
35
34th
|
41
52nd
|
| IS momentum | 58
25th
|
70
43rd
|
82
68th
|
| IS risk (safety) | 100
62nd
|
80
38th
|
50
21st
|
| IS quality | 83
83rd
|
60
45th
|
59
41st
|
| IS balance sheet | 76
83rd
|
44
41st
|
21
21st
|
| IS earnings quality | 75
79th
|
70
55th
|
70
59th
|
| IS cash flow | 64
66th
|
43
41st
|
71
79th
|
| Piotroski F-score (0-9) | 7
59th
|
5
28th
|
7
59th
|
| Altman Z-score | 5.7
72nd
|
3.2
41st
|
1.9
24th
|
| Beneish M-score | −2.56
64th
|
−0.61
96th
|
−2.69
25th
|
| Ohlson O-score | −8.01
52nd
|
−8.62
38th
|
−6.50
69th
|
| IS credit score | 87
83rd
|
58
34th
|
44
24th
|
Size (TTM)
8 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| Market cap | $39.6B
76th
|
$42.9B
79th
|
$43.9B
83rd
|
| Revenue | $4.5B
69th
|
$4.6B
76th
|
$17.0B
93rd
|
| EBITDA | $1.4B
76th
|
$895.8M
66th
|
$3.5B
93rd
|
| Net income | $825.0M
72nd
|
$166.1M
55th
|
$1.4B
90th
|
| Free cash flow | $939.0M
72nd
|
$398.5M
55th
|
$2.6B
93rd
|
| Total assets | $6.7B
66th
|
$24.8B
90th
|
$29.9B
93rd
|
| Shareholders' equity | $2.8B
62nd
|
$15.2B
93rd
|
$6.2B
72nd
|
| Employees | 8,600
59th
|
7,900
55th
|
94,000
97th
|
Price performance
9 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| 1 day | −2.0% | −1.6% | −1.5% |
| 1 week | −5.6% | +0.8% | +2.7% |
| 1 month | +7.1% | +1.7% | −0.9% |
| 3 months | +42.2% | +22.2% | +30.9% |
| 6 months | +95.2% | +33.3% | +51.3% |
| Year to date | +95.4% | +14.4% | +18.5% |
| 1 year | +182.3% | +31.5% | +31.4% |
| 3 years, cumulative | +95.9% | +64.2% | +30.5% |
| 5 years, cumulative | −34.1% | +27.3% | +10.2% |
Technicals
4 measures| Measure | ILMN | WAT | IQV |
|---|---|---|---|
| RSI 14 | 53.1 | 55.9 | 54.9 |
| From 52-week high | −15.1% | −3.9% | −3.8% |
| From 52-week low | +180.8% | +54.5% | +72.8% |
| Beta | 1.42 | 1.15 | 1.17 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17